Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance

被引:54
作者
Maeda, S [1 ]
Yoshida, H [1 ]
Ogura, K [1 ]
Kanai, F [1 ]
Shiratori, Y [1 ]
Omata, M [1 ]
机构
[1] Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, Tokyo 113, Japan
关键词
Helicobacter pylori; eradication; clarithromycin; resistance; point mutation;
D O I
10.1136/gut.43.3.317
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background - Clarithromycin is one of the most important antibiotics for Helicobacter pylori eradication. However, 5-10% of strains are reported to be resistant. It has been shown that one point mutation in the 23S rRNA gene is associated with resistance to clarithromycin. Aims - To establish a polymerase chain reaction (PCR) system which amplifies a segment of the 23S rRNA gene containing the mutation points with primers specific for H pylori, so that H pylori infection and the mutation associated with clarithromycin resistance can be examined simultaneously. Methods - To detect H pylori infection and the mutation simultaneously, primers specific for the H pylori 23S rRNA gene were designed based on sequence conservation among H pylori strains and sequence specificity as compared with other bacteria. DNA from 57 cultured strains and from 39 gastric juice samples was amplified in the seminested 23S rRNA PCR. Clinical applicability was evaluated in 85 patients. Results - DNA samples from 57 cultured strains were all amplified. The novel assay and the urease A PCR agreed in 37/39 gastric juice samples with no false positives. The assay did not amplify the DNA of bacteria other than H pylori. Eight of 85 samples had the mutation before treatment. In clarithromycin based treatment, eradication was achieved in 2/5 (40%) with the mutation and 29/34 (85%) without the mutation. Conclusion - The assay using gastric juice is quick (within 12 hours) and noninvasive (endoscopy not required), enabling rapid initiation of appropriate antibiotic treatment.
引用
收藏
页码:317 / 321
页数:7
相关论文
共 21 条
[1]  
Cayla R., 1995, Gut, V37, pA55
[2]  
Chiba N, 1996, AM J GASTROENTEROL, V91, P2139
[3]  
DebetsOssenkopp YJ, 1996, FEMS MICROBIOL LETT, V142, P37, DOI 10.1016/0378-1097(96)00239-X
[4]   Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy [J].
Gotoh, A ;
Kawakami, Y ;
Akahane, T ;
Akamatsu, T ;
Shimizu, T ;
Kiyosawa, K ;
Katsuyama, T .
MICROBIOLOGY AND IMMUNOLOGY, 1997, 41 (01) :7-12
[5]   EFFECT OF TREATMENT OF HELICOBACTER-PYLORI INFECTION ON THE LONG-TERM RECURRENCE OF GASTRIC OR DUODENAL-ULCER - A RANDOMIZED, CONTROLLED-STUDY [J].
GRAHAM, DY ;
LEW, GM ;
KLEIN, PD ;
EVANS, DG ;
EVANS, DJ ;
SAEED, ZA ;
MALATY, HM .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (09) :705-708
[6]   Nested-polymerase chain reaction for the detection of Helicobacter pylori infection with novel primers designed by sequence analysis of urease A gene in clinically isolated bacterial strains [J].
Kawamata, O ;
Yoshida, H ;
Hirota, K ;
Yoshida, A ;
Kawaguchi, R ;
Shiratori, Y ;
Omata, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 219 (01) :266-272
[7]  
LABENZ J, 1995, EUR J GASTROEN HEPAT, V7, P9
[8]  
Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x
[9]   Metronidazole resistance: A predictor of failure of Helicobacter pylori eradication by triple therapy [J].
Midolo, PD ;
Lambert, JR ;
Turnidge, J .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1996, 11 (03) :290-292
[10]   HELICOBACTER-PYLORI INFECTION AND GASTRIC-CARCINOMA AMONG JAPANESE-AMERICANS IN HAWAII [J].
NOMURA, A ;
STEMMERMANN, GN ;
CHYOU, PH ;
KATO, I ;
PEREZPEREZ, GI ;
BLASER, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (16) :1132-1136